AbbVie Inc. (ABBV) is an American publicly traded biopharmaceutical company that develops and markets advanced therapies addressing some of the world's most complex and serious diseases. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has a diverse portfolio that includes treatments for conditions like rheumatoid arthritis, psoriasis, Crohn's disease and HIV, among others. The company's headquarters are in North Chicago, Illinois.
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. They aim to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
AbbVie is perhaps best known for its blockbuster drug, Humira (adalimumab), which is used for treating autoimmune diseases. Since its FDA approval in 2002, Humira has become one of the world's best-selling drugs, generating revenue of over $10 billion annually for AbbVie.
AbbVie's commitment to innovation is demonstrated by their investment in research and development. The company invests nearly half of its net revenues in their R&D program each year, reflecting the emphasis they put on creating new solutions and improving existing treatments for serious health conditions. The company's robust pipeline includes programs in the areas of oncology, immunology, neuroscience, and virology.
In 2020, AbbVie completed a $63 billion acquisition of Allergan, a pharmaceutical company that manufactures popular products such as Botox. This acquisition expanded AbbVie's business model beyond reliance on individual products like Humira, and diversified its revenue streams.
AbbVie takes corporate responsibility seriously and runs numerous initiatives aiming at promoting sustainable practices. The company has set targets in areas like energy usage, reduction of greenhouse gas emissions, and waste to landfill, and has launched the STEM for Girls initiative, aimed at encouraging girls to pursue interest and studies in science, technology, engineering, and math.
The company's stock, which trades under the ticker symbol 'ABBV' on the New York Stock Exchange, offers an attractive option for investors due to its strong performance, as well as its commitment to a reliable dividend payout.
In conclusion, with its extensive and diverse portfolio of healthcare solutions, investments in research and development, and commitment to corporate responsibility, AbbVie Inc. is a global leader in the biopharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
An investment of $250,000 split evenly across UnitedHealth Group, Merck, AbbVie, and Pfizer could generate approximately $8,018 in annual passive income, offering a blended yield of 3.21%. While Pfizer provides the highest income, it also presents the most risk due to a frozen dividend. AbbVie and UnitedHealth show greater dividend safety with recent raises and wider coverage cushions, making healthcare a stable sector for retirement income.
AbbVie reported strong Q3 2026 financial results, with adjusted EPS exceeding guidance and total net revenues of $17.4 billion. The company raised its full-year revenue guidance and announced a 5.2% increase in its quarterly dividend, driven by robust sales growth from key products like Skyrizi and Rinvoq. Strategic acquisitions, pipeline advancements in immunology, neuroscience, and oncology, and new drug approvals are expected to fuel continued long-term growth.
AbbVie Inc. reported third-quarter results that surpassed analyst expectations in both adjusted earnings per share and revenue. Despite beating estimates and raising full-year guidance, the stock experienced a premarket dip of 3% as the updated guidance largely aligned with Wall Street's existing estimates. The company saw strong performance in its immunology and neuroscience portfolios, though Humira sales continued to decline due to biosimilar competition, and it also announced a dividend increase.
This article highlights three small biotechnology companies—iBio (IBIO), Kalaris Therapeutics (KLRS), and OnKure Therapeutics (OKUR)—that have recently attracted substantial investment from Matthew Perry's Coastlands Capital. Perry, an experienced biotech investor, believes these beaten-down stocks present significant opportunities due to their promising pipelines, upcoming clinical milestones, and in some cases, attractive valuations relative to cash. The author emphasizes the value of following specialist investors in the complex biotech sector to identify potential high-growth companies.
AbbVie (ABBV) has delivered a significant return for investors over the past decade, turning an initial $1,000 investment into $7,464, significantly outperforming the S&P 500. This growth was driven by a successful transition away from its blockbuster drug Humira through new immunology drugs like Skyrizi and Rinvoq, as well as strategic acquisitions like Allergan and Apogee Therapeutics. The company's quarterly dividend also tripled during this period, compounding investor returns.
AbbVie Inc. (ABBV) stock rallied 1.68% to $290.79 on Thursday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This gain broke a two-day losing streak for the stock.